Dihexa is a synthetic analogue of angiotensin IV, built at Washington State University by cutting the parent peptide down to its Tyr-Ile core.
Amounts reported for Dihexa are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No human amount or schedule has been recorded for this compound.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 4 preclinical and 4 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical4 rows | |||||
| Original oral dose-finding in rat dementia modelsRats with scopolamine-induced memory deficits and aged rats, tested in the Morris water maze | Oral doses in the scopolamine and aged-rat models; the indexed abstract states no figure, and secondary summaries give about 2 mg/kg per day | Not stated | Oral | Not stated | Journal of Pharmacology and Experimental Therapeutics (PubMed)2013 |
| This is the paper that first described Dihexa, reporting that the modified tripeptide core stayed active by mouth, reversed scopolamine-induced water-maze deficits and increased hippocampal synaptogenesis. The record carries a 2021 expression of concern printed by the journal, so its specifics deserve extra caution, and every figure in it is a rat figure that does not convert to a human amount. | |||||
| APP/PS1 Alzheimer-model miceAPP/PS1 transgenic mice dosed from six to nine months of age, with wild-type controls | 1.44 mg/kg or 2.88 mg/kg | Once daily | Intragastric | 3 monthsNone described | Brain Sciences (PubMed Central)2021 |
| Both amounts shortened water-maze escape latency, raised neuronal counts and synaptophysin, lowered IL-1 beta and TNF-alpha and raised IL-10, and the effect was reversed by the PI3K inhibitor wortmannin. The methods are mostly written as intragastric dosing but one sentence says intraperitoneal, so the route in this study is not stated consistently. | |||||
| Rat sciatic nerve transection and repairMale Lewis rats, 6 to 8 per group across 10 experimental groups | 2-4 mg/kg body weight | Not stated | Local hydrogel at the repair site, systemically by vein or abdomen, or into the gastrocnemius muscle | Function followed to 16 weeks after repairNot applicable | Annals of Medicine and Surgery (PubMed Central)2021 |
| Motor function measured by walking footprint grades improved significantly at 8 to 16 weeks when Dihexa or G-CSF was given into the muscle alongside mesenchymal stem cells, and foot flexion contractures were reduced. Sensory recovery was similar across all groups, and Dihexa was not tested on its own against vehicle in a way that separates its contribution. | |||||
| Huntington's disease model in rats (negative result)40 male Wistar rats randomised to vehicle, 3-nitropropionic acid, or 3-nitropropionic acid plus Dihexa | Not stated in the report; 40 rats were split across 3 groups | Not stated | Not stated in the report | 5 weeksNot applicable | Journal of Huntington's Disease (PubMed)2024 |
| Dihexa, named here by its code PNB-0408, did not protect rats from the weight loss, spatial learning deficits or motor dysfunction caused by the mitochondrial toxin. This is a published negative result in the same compound class that produced the memory findings, and the authors call for work in other models. | |||||
| Community-reported4 rows | |||||
| Vendor capsule product | 5 mg per capsule, 60 capsules per bottle (300 mg total) | Not stated | Oral capsule | Not stated | Community resource2026 |
| This is a vendor claim about what ships, not a protocol. The listing publishes a per-lot certificate: lot 060526 was reported at 99.90 percent purity by HPLC with 5.36 mg measured against a 5 mg label. The page states plainly that the product is not for human, veterinary or food use. | |||||
| Vendor nasal spray kit | 100 mcg per spray, about 100 sprays per 10 mL bottle (10 mg total) | Not stated | Intranasal, supplied pre-mixed with no reconstitution | Not stated | Community resource2026 |
| The aerosol listing is the reason this compound has nasal-spray support in the calculator. The lot certificate reports identity confirmed and 0.1 mg measured against a 100 mcg label. No published study has given Dihexa intranasally to any species, so the route here is a product format rather than a studied one. | |||||
| Community dosing band | 10-40 mg per day | Daily, usually in the morning | Oral or intranasal | Not stated | Community resource2026 |
| This 2026 guide rates the evidence low, counts a single peer-reviewed citation behind the compound and labels every half-life and dose figure vendor folklore until a paper exists. It also warns against treating the widely repeated synaptogenic potency comparison as a clinical multiplier. | |||||
| What community users report against the cited figure | About 2 mg/kg per day in rats is the only cited figure; community reports describe a few milligrams a day | Daily, in short runs | Oral, sometimes applied to the skin or injected | Not stated | Community resource2026 |
| This 2026 summary states that the rat figure does not translate to a person and was never validated in people, and that the practical risk is sourcing: Dihexa is sold only as an unregulated research chemical, so purity, the real amount in the container and sterility all vary. | |||||
Plus 6 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Dihexa is a synthetic analogue of angiotensin IV, built at Washington State University by cutting the parent peptide down to its Tyr-Ile core and capping both ends so the molecule survives digestion and reaches the brain. It has been tested only in rats, mice, zebrafish and cell culture, where it is reported to act on the hepatocyte growth factor and c-Met system and to restore memory in scopolamine-treated and aged animals. No human study of Dihexa has ever been registered, the 2014 paper that established its mechanism was retracted in 2025, and vendors sell it both as oral capsules and as a pre-mixed nasal spray for research use only.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Neuroplasticity, cognition, stress and sleep models.
This is the paper that first described Dihexa, reporting that the modified tripeptide core stayed active by mouth, reversed scopolamine-induced water-maze deficits and increased hippocampal synaptogenesis. The record.
Both amounts shortened water-maze escape latency, raised neuronal counts and synaptophysin, lowered IL-1 beta and TNF-alpha and raised IL-10, and the effect was reversed by the PI3K inhibitor wortmannin. The methods.
Motor function measured by walking footprint grades improved significantly at 8 to 16 weeks when Dihexa or G-CSF was given into the muscle alongside mesenchymal stem cells, and foot flexion contractures were reduced..
Dihexa, named here by its code PNB-0408, did not protect rats from the weight loss, spatial learning deficits or motor dysfunction caused by the mitochondrial toxin. This is a published negative result in the same.
This is a vendor claim about what ships, not a protocol. The listing publishes a per-lot certificate: lot 060526 was reported at 99.90 percent purity by HPLC with 5.36 mg measured against a 5 mg label. The page states.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
4 protocol rows describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
4 rows record what blogs, vendor write-ups or forums describe for Dihexa. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
PNB-0408, ATH-1001, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, Hexanoyl-Tyr-Ile-Ahx-NH2, UNII 9WYX65A5C2, DTXSID701032895
XEUVNVNAVKZSPT-JTJYXVOQSA-N
(2S,3S)-N-(6-amino-6-oxohexyl)-2-[[(2S)-2-(hexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanamide
7 curated references, each with its journal, year and study model, plus 6 community resources reported but not linked.